J Med Genet doi:10.1136/jmedgenet-2012-101511
  • Cancer genetics
  • Original article

Refining the role of pms2 in Lynch syndrome: germline mutational analysis improved by comprehensive assessment of variants

  1. Gabriel Capellá1
  1. 1Hereditary Cancer Program, Catalan Institute of Oncology, ICO-IDIBELL, Hospitalet de Llobregat, Barcelona, Spain
  2. 2Institute of Molecular and Oncological Medicine of Asturias, IMOMA, Oviedo, Spain
  3. 3Medical Clinic 1, Johann Wolfgang Goethe-University, Frankfurt, Germany
  4. 4Hereditary Cancer Program, Catalan Institute of Oncology, ICO-IdIBGI, Girona, Spain
  5. 5Department of Pathology, University Hospital of Bellvitge, Hospitalet de Llobregat, Barcelona, Spain
  6. 6Department of Pathology, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
  7. 7Department of Human and Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands
  1. Correspondence to Dr Gabriel Capellá and Dr Marta Pineda, Hereditary Cancer Program, Catalan Institute of Oncology, ICO-IDIBELL, Gran Via 199-203, 08908 Hospitalet de Llobregat, Barcelona, Spain; gcapella{at} and mpineda{at}
  • Received 3 January 2013
  • Revised 25 April 2013
  • Accepted 28 April 2013
  • Published Online First 24 May 2013


Background and aim The majority of mismatch repair (MMR) gene mutations causing Lynch syndrome (LS) occur either in MLH1 or MSH2. However, the relative contribution of PMS2 is less well defined. The aim of this study was to evaluate the role of PMS2 in LS by assessing the pathogenicity of variants of unknown significance (VUS) detected in the mutational analysis of PMS2 in a series of Spanish patients.

Methods From a cohort of 202 LS suspected patients, 13 patients showing loss of PMS2 expression in tumours were screened for germline mutations in PMS2, using a long range PCR based strategy and multiplex ligation dependent probe amplification (MLPA). Pathogenicity assessment of PMS2 VUS was performed evaluating clinicopathological data, frequency in control population and in silico and in vitro analyses at the RNA and protein level.

Results Overall 25 different PMS2 DNA variants were detected. Fourteen were classified as polymorphisms. Nine variants were classified as pathogenic: seven alterations based on their molecular nature and two after demonstrating a functional defect (c.538-3C>G affected mRNA processing and c.137G>T impaired MMR activity). The c.1569C>G variant was classified as likely neutral while the c.384G>A remained as a VUS. We have also shown that the polymorphic variant c.59G>A is MMR proficient.

Conclusions Pathogenic PMS2 mutations were detected in 69% of patients harbouring LS associated tumours with loss of PMS2 expression. In all, PMS2 mutations account for 6% of the LS cases identified. The comprehensive functional analysis shown here has been useful in the classification of PMS2 VUS and contributes to refining the role of PMS2 in LS.

Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of JMG.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article